Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 3/2013

01-03-2013 | Research Article

Effectiveness of oxaliplatin desensitization protocols

Authors: Susana Cortijo-Cascajares, Inmaculada Nacle-López, Ignacio García-Escobar, María José Aguilella-Vizcaíno, Alberto Herreros-de-Tejada, Hernán Cortés-Funes Castro, Miguel-Ángel Calleja-Hernández

Published in: Clinical and Translational Oncology | Issue 3/2013

Login to get access

Abstract

Introduction

Hypersensitivity reaction (HSR) to antineoplastic drugs can force doctors to stop treatment and seek other alternatives. These alternatives may be less effective, not as well tolerated and/or more expensive. Another option is to use desensitization protocols that induce a temporary state of tolerance by gradually administering small quantities of the antineoplastic drug until the therapeutic dosage is reached. The aim of this study is to assess the effectiveness of oxaliplatin desensitization protocols.

Materials and methods

A retrospective observational study was carried out between January 2006 and May 2011. The inclusion criteria were patients undergoing chemotherapy treatment with oxaliplatin who had developed an HSR to the drug and who were candidates for continuing the treatment using a desensitization protocol. The patients’ clinical records were reviewed and variables were gathered relating to the patient, the treatment, the HSR, and the desensitization protocol administered. The data were analysed using version 18.0 of the statistics program SPSS.

Results

A total of 53 desensitization protocols were administered to 21 patients. In 89 % of these cases, no new reactions occurred while the drug was being administered. New reactions of mild severity only occurred in 11 % of cases, and none of these reactions were severe enough for treatment to be stopped. All patients were able to complete the desensitization protocol.

Conclusion

This study confirms that oxaliplatin desensitization protocols are safe and effective and allow patients to continue with the treatment that initially caused an HSR.
Literature
1.
Lee C, Gianos M, Klaustermeyer WB (2009) Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 102:179–187PubMedCrossRef
2.
Syrigou E, Syrigos K, Saif MW (2008) Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. Curr Allergy Asthma Rep 8:56–62PubMedCrossRef
3.
Pagani M (2010) The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization. Med Clin North Am 94:835–852PubMedCrossRef
4.
Polyzos A, Tsavaris N, Gogas H, Souglakos J, Vambakas L, Vardakas N et al (2008) Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. Oncology 76:36–41PubMedCrossRef
5.
Medioni J, Coulon MA, Morere JF, Hennebelle F, Piperno-Neumann S, Breau JL (1999) Anaphylaxis after oxaliplatin. Ann Oncol 10:610PubMedCrossRef
6.
De Vries RS, Mattijssen EJ, van Sorge AA (2006) Serious delayed hypersensitivity reaction to oxaliplatin. Ann Oncol 17:1723–1724PubMedCrossRef
7.
Potenza S, Nasti G, Alessandro O, Filippelli A, Rossi F, Capuano A (2010) Severe respiratory symptoms to oxaliplatin infusion: a case report of delayed hypersensitivity reaction. Investig New Drugs 28:185–186CrossRef
8.
Köhlmoos C, Marquardt GG, Brinkmann D, Meier K (2008) Allergic reactions to oxaliplatin therapy—an overview. Eur J Oncol Pharm 2:27–28
9.
Siu S, Chan R, Au G (2006) Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol 17:259PubMedCrossRef
10.
Shao YY, Hu FC, Liang JT, Chiu WT, Cheng AL, Yang CH (2010) Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions. J Formosan Med Assoc 109:362–368PubMedCrossRef
11.
Kim BH, Bradley T, Tai J, Budman DR (2009) Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology 76:231–238PubMedCrossRef
12.
Mori Y, Nishimura T, Kitano T, Yoshimura K, Matsumoto S, Kanai M et al (2010) Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX. Oncology 79:136–143PubMedCrossRef
13.
Bhargava P, Gammon D, McCormick MJ (2004) Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 100:211–212PubMedCrossRef
14.
Brandi G, Pantaleo M, Galli C, Falcone A, Antonuzzo A, Mordenti P et al (2003) Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 89:477–481PubMedCrossRef
15.
Kidera Y, Satoh T, Ueda S, Okamoto W, Okamoto I, Fumita S et al (2011) High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin. Int J Clin Oncol. doi:10.​1007/​s10147-010-0170-6:​1-6
16.
Maindrault-Goebel F, André T, Tournigand C, Louvet C, Perez-Staub N, Zeghib N et al (2005) Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 41:2262–2267PubMedCrossRef
17.
Thomas RR, Quinn MG, Schuler B, Grem JL (2003) Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 97:2301–2307PubMedCrossRef
18.
Tonini G, Santini D, Vincenzi B, Borzomati D, Dicuonzo G, La Cesa A et al (2002) Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients. J Biol Regul Homeost Agents 16:105–109PubMed
19.
Ulrich-Pur H, Fiebiger WCC, Schüll B, Kornek GV, Scheithauer W, Raderer M (2000) Oxaliplatin-induced fever and release of IL-6. Oncology 59:187–189PubMedCrossRef
20.
Wilson C, Purcell C, Seaton A, Oladipo O, Maxwell PJ, O’Sullivan JM, Wilson R, Johnston PG, Waugh D (2012) Chemotherapy-induced CXC-chemokine/CXC-chemokine Receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. J Pharmacol Exp Ther 327:746–759CrossRef
21.
Kast R, Scheuerle A, Wirtz C, Karpel-Massler G, Halatsch ME (2011) The rationale of targeting neutrophils with dapsone during glioblastoma treatment. Anti Cancer Agents Med Chem 11:756–761CrossRef
22.
Edmondson DA, Gruling BJ, Urmanski AM, Wong SJ, Levy MB (2007) Oxaliplatin hypersensitivity: case report and successful repeat desensitization. Am J Ther 14:116–118PubMedCrossRef
23.
Gammon D, Bhargava P, McCormick MJ (2004) Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol. Oncologist 9:546PubMedCrossRef
24.
Meyer L, Zuberbier T, Worm M, Oettle H, Riess H (2002) Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. J Clin Oncol 20:1146PubMed
25.
Castells MC, Tennant NM, Sloane DE, Ida Hsu F, Barrett NA, Hong DI et al (2008) Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 122:574–580PubMedCrossRef
26.
Habert H, Castagne V (2009) Management of hypersensitivity to oxaliplatin at the Paul Brousse hospital pharmacy department: desensitization protocol and clinical impact. Pharm World Sci 31:96–97
27.
Syrigou EI, Karapanagiotou EM, Alamara CV, Boura PG, Saif MW, Syrigos KN (2009) Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. Clin Colorectal Cancer 8:106–109CrossRef
28.
Gottlieb GR, Bordoni RE, Lawhead RA Jr, Feinberg BA (2010) Successful outpatient desensitization of cancer patients with hypersensitivity reactions to chemotherapy. Community Oncol 7:452–457CrossRef
29.
Herrero T, Tornero P, Infante S, Fuentes V, Sanchez M, De Barrio M et al (2006) Diagnosis and management of hypersensitivity reactions caused by oxaliplatin. J Investig Allergol Clin Immunol 16:327PubMed
30.
Gastaminza G, de la Borbolla JM, Goikoetxea MJ, Escudero R, Antón J, Espinós J et al (2011) A new rapid desensitization protocol for chemotherapy agents. J Investig Allergol Clin Immunol 21:108–112PubMed
31.
Garufi C, Cristaudo A, Vanni B, Bria E, Aschelter AM, Santucci B et al (2003) Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol 14:497–498PubMedCrossRef
32.
Rubbia-Brandt L, Tauzin S, Brezault C, Delucinge-Vivier C, Descombes P, Dousset B, Majno PE, Mentha G, Benoit T (2011) Gene expression profiling provides insights into pathways of oxaliplatin-related sinusoidal obstruction syndrome in humans. Mol Cancer Ther 10:687–696PubMedCrossRef
Metadata
Title
Effectiveness of oxaliplatin desensitization protocols
Authors
Susana Cortijo-Cascajares
Inmaculada Nacle-López
Ignacio García-Escobar
María José Aguilella-Vizcaíno
Alberto Herreros-de-Tejada
Hernán Cortés-Funes Castro
Miguel-Ángel Calleja-Hernández
Publication date
01-03-2013
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 3/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0909-9

Other articles of this Issue 3/2013

Clinical and Translational Oncology 3/2013 Go to the issue

Research Article

Development and characterization of an isogenic cell line with a radioresistant phenotype

Research Article

Identification of valid reference housekeeping genes for gene expression analysis in tumor neovascularization studies

Research Article

Decreased expression of chromodomain helicase DNA-binding protein 5 is an unfavorable prognostic marker in patients with primary gallbladder carcinoma

Research Article

IMRT: preliminary results in a series of advanced head-and-neck cancer patients

Correspondence

DeCIDE and PARADIGM: nails in the coffin of induction chemotherapy in head and neck squamous cell carcinoma?

Special Article

Viruses in cancer treatment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits